Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

ACTIVE NOT RECRUITING Phase 2

NYX-458 in Subjects With Mild Cognitive Impairment or Mild Dementia Due to Parkinson's Disease or Lewy Body Dementia (Cognition, Memory, Attention, Thinking)

NCT04148391 · View on ClinicalTrials.gov ↗

Study Summary

A Study to Evaluate NYX-458 in Subjects With Mild Cognitive Impairment or Mild Dementia Associated With Parkinson's Disease or Prodromal or Manifest Lewy Body Dementia

Interventions

  • DRUG Placebo Oral Capsule
  • DRUG NYX-458

Study Locations (20)

Florida

  • Aptinyx Clinical Site — Boca Raton
  • Aptinyx Clinical Site — Bradenton
  • Aptinyx Clinical Site — Miami
  • Aptinyx Clinical Site — Miami
  • Aptinyx Clinical Site — Miami
  • Aptinyx Clinical Site — Miami
  • Aptinyx Clinical Site — Miami Lakes
  • Aptinyx Clinical Site — Orlando
  • Aptinyx Clinical Site — Port Charlotte
  • Aptinyx Clinical Site — Port Orange
  • Aptinyx Clinical Site — Sunrise

California

  • Aptinyx Clinical Site — Fresno
  • Aptinyx Clinical Site — Simi Valley

Arizona

  • Aptinyx Clinical Site — Scottsdale

Georgia

  • Aptinyx Clinical Site — Decatur

Michigan

  • Aptinyx Clinical Site — Farmington Hills

Minnesota

  • Aptinyx Clinical Site — Golden Valley

New Jersey

  • Aptinyx Clinical Site — Toms River

New York

  • Aptinyx Clinical Site — Poughkeepsie

Trial Details

FieldValue
Enrollment Target 99 participants
Start Date 2019-11-14
Est. Completion 2022-12-30
Phase Phase 2

Sponsor

Aptinyx

1 total trials

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT04148391

The ClinicalTrials.gov registry entry for NCT04148391 describes a study currently listed as active not recruiting. It is categorized as Phase 2, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 99 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Aptinyx, which has 1 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 4 conditions, with Parkinson Disease appearing as the primary indexed condition, and to 2 interventions — of which Placebo Oral Capsule is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT04148391 reports 20 study locations spanning 9 distinct geographic areas — top geographies include Florida, California, Arizona. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT04148391 about?

NCT04148391 is a clinical study titled "NYX-458 in Subjects With Mild Cognitive Impairment or Mild Dementia Due to Parkinson's Disease or Lewy Body Dementia (Cognition, Memory, Attention, Thinking)". A Study to Evaluate NYX-458 in Subjects With Mild Cognitive Impairment or Mild Dementia Associated With Parkinson's Disease or Prodromal or Manifest Lewy Body Dementia

What is the current status of trial NCT04148391?

This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 99 participants. The study started on 2019-11-14. Estimated completion is 2022-12-30.

What conditions does trial NCT04148391 study?

This clinical trial studies the following conditions: Parkinson Disease, Mild Cognitive Impairment, Lewy Body Disease, Mild Dementia. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT04148391?

The interventions under investigation include: Placebo Oral Capsule (DRUG), NYX-458 (DRUG). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT04148391?

This trial is sponsored by Aptinyx, which has 1 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT04148391 being conducted?

This trial has 20 study locations across Arizona, California, Florida, Georgia, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial